Advanced Genetic Profiling Transforms Metastatic Prostate Cancer Care
Advanced prostate cancer treatments are shifting toward personalized genetic profiling and targeted therapies. Experts highlight that combining biological drugs with hormonal pills cuts disease progression risks by half.
Advanced and metastatic prostate cancer presents complex medical and psychological challenges for patients and their families. For decades, the standard therapeutic approach relied on uniform hormonal suppression. However, recent scientific breakthroughs are completely transforming diagnosis and treatment methods.
"Our goal is to send a clear message to the public: metastatic prostate cancer is no longer a disease with a one-size-fits-all treatment," explains Dr. Daniel Keizman, an oncology expert and head of the Uro-Oncology Unit at the Oncology Division of Ichilov Hospital (Tel Aviv Sourasky Medical Center). "Today, we possess precise tools based on the genetic profile of the tumor, enabling us to deliver targeted therapy."
Genetic Profiling and Tumor Vulnerabilities
Prostate cancer traditionally feeds on male hormones such as testosterone, making hormonal suppression the primary historical treatment. Over time, however, tumors can develop resistance and progress. Experts have discovered that in a significant portion of patients—up to a quarter of those with metastatic disease—specific genetic mutations exist that affect DNA repair mechanisms within the cell.
When these mutations are present, the disease tends to behave more aggressively and rapidly. Identifying these genetic mutations has become a turning point in the treatment pathway. Detecting the mutation through a simple blood test or a tumor biopsy allows physicians to uncover the tumor's Achilles' heel and tailor a precise treatment.
Breakthrough: Dual-Action Combination Therapies
While past treatments relied on testosterone-lowering injections, single hormonal therapies, or chemotherapy without genetic matching, modern oncology utilizes advanced biological drugs that inhibit DNA repair mechanisms. The core innovation lies in combining biological treatment with advanced hormonal therapy in a single pill.
Dr. Keizman explains the mechanism:
"This combination attacks the tumor from two different directions simultaneously: it blocks the hormonal fuel while preventing cancer cells from repairing their damaged DNA, ultimately leading to their destruction."
Clinical studies have demonstrated that this integrated approach cuts the risk of disease progression by roughly half and dramatically delays the onset of metastatic pain.
Medical Monitoring and Quality of Life
Administering advanced combination therapies requires close medical supervision to ensure efficacy while preserving the patient's daily routine and quality of life. Because the treatment involves two powerful mechanisms, side effects such as fatigue, anemia, blood pressure fluctuations, or electrolyte imbalances may occur.
Physicians emphasize that these side effects are fully manageable through regular blood tests, blood pressure monitoring, and temporary dosage adjustments when necessary. Furthermore, administering a low-dose steroid as part of the protocol maintains electrolyte balance and prevents fluid retention, allowing patients to maintain independence and a good quality of life at home.
Experts stress the vital importance of awareness and accessibility to advanced technologies. Patients diagnosed with advanced or metastatic prostate cancer are advised to request a genetic profiling of their tumor, as identifying a genetic flaw can unlock access to advanced, life-saving therapies that were previously unavailable.
